glenmark pharmaceuticals (Citi) NBE Licensing Deal - Cash Flows and Validation

R&D back in focus; Raise TP to Rs395; First deal for an NBE; What does Glenmark get?; Clearly positive; We value at Rs35/sh
Date Rating Target Price Recommendation Price Broker house
16 May 2011 buy 395 (From 360) 305 Citi Report

No comments:

Post a Comment